Quality of life in patients with chordomas/chondrosarcomas during treatment with proton beam therapy

Abstract

Introduction: Health-related quality of life (HQL) parameters have never been tested in patients having chondromas/chondrosarcomas who are being treated with protons. The aim of this study was to document changes in HQL of chordoma/chondrosarcoma patients treated with proton beam radiotherapy. Treatments commenced in September 2011 at CNAO, and HQL studies were initiated in January 2012 for all patients undergoing treatment. Methods: The validated Italian translation of the EORTC QLQ-C30 version 3.0 was used for HQL evaluation. The HQL assessments were made prior to starting radiation and at completion of treatment. Scoring was as per the EORTC manual. As per standard norms, a difference of >10 points in the mean scores was taken to be clinically meaningful. Results: Between January and September 2012, 17 patients diagnosed with chordoma or chondrosarcoma, with a mean ± SD age of 49.5 ± 16.4 years, had completed treatment. The involved sites were skull base (n = 12) and sacral/paraspinal (n = 5). The prescribed dose was 70–74 GyE at 2 GyE per fraction, 5 days/week. When comparing pre- and post-treatment scores, neither a clinically meaningful nor a statistically significant change was documented. Conclusions: During treatment, HQL is not adversely affected by protons, allowing normal life despite the long course of treatment. This is an ongoing study and more long-term assessment will help evaluate the actual impact of proton therapy on HQL for these slow-responding tumours.

Health‐related quality of life, psychosocial functioning, and unmet health needs in patients with sarcoma: A systematic review

“…Four studies reported HRQoL data from patients at both diagnostic and treatment phases. [39][40][41][42] Patients with sarcoma Compared with the general population, patients with sarcoma reported lower mean scores on all HRQoL scales, resulting in a lower mean global health score. 39 Compared with pretreatment scores, patients with sarcoma treated with radiotherapy and/or chemotherapy reported lower physical functioning, and more fatigue, nausea/vomiting, appetite loss, but less pain and a higher overall HRQoL score.…”

What questionnaires to use when measuring quality of life in sacral tumor patients: the updated sacral tumor survey

“…To determine what issues should be addressed in a survey for patients with sacral tumors, we hypothesized the existence of six domains based on the current literature: mental health, physical health, pain, gastrointestinal symptoms, sexual function, and urinary incontinence [6, 7, 27, 36, 39, 41, 45]. To assess content validity, we contacted 80 patients (of whom 32 responded, i.e.…”

“…The impact of these major surgeries on neurological, physical, psychological, social, and emotional functioning is substantial and can have a major impact on a patients’ quality of life [7, 27, 31, 36, 44]. It is important to accurately measure these outcomes in order to: (1) understand the impact of treatment on patients, (2) educate future patients, and (3) compare treatments.…”

Management of sinonasal and skull base nonmesenchymal chondrosarcoma, a narrative review

“…Similarly Rosenberg et al (5) reported LC rates at 5 and 10 years of 99% and 98%, respectively, and OS of 99% at 5 and 10 years when treating 200 CS with surgery then proton beam therapy; similar results have been reported by others (71) . Encouragingly, Srivastava et al (72) report that proton beam therapy does not have a significant impact on health-related quality of life parameters.…”